Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

enviromax technologies pty ltd - bifenthrin - insecticide - apple | banana | bowling green | commercial building/structure - external | commercial building/structure-internal | commercial/ - african black beetle | ants (except red imported fire ant) | aphid | apple dimpling bug - c. liebknechti | argentine stem weevil | banana flower thrips | banana scab moth | bill bug | biting midge | black or black house ant | caterpillar | coastal brown ant | cockroach | codling moth | corn earworm | cutworm - agrotis spp. | flea | flower thrip | fly | funnel ant | geranium plume moth | greenhouse whitefly | helicoverpa spp. | lawn armyworm | light brown apple moth | longtailed mealy bug | looper | meat ant | mosquito | native budworm or bollworm | paper nest wasp | pear looper | plague thrips | poinsettia whitefly | sod webworm | spider | stinging ant | subterranean termite | subterranean termite ex. m. darwiniensis | subterranean termite incl. m.darwiniensi | sugar ant | thrips simplex | tick - except paralysis tick | timber beetle | two spotted mite | adult mosquitoes | banded sugar ant | billbug | budworm | campylomma livida | coptotermes spp. | corn earworm | cotton bollworm | cotton whitefly | ctenoceph

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

max(rudong) chemicals co., ltd. - ethephon (as anti-cholinesterase compound) - soluble concentrate - ethephon (as anti-cholinesterase compound) organophosphorus active 900.0 g/l - growth regulator

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: colloidal anhydrous silica; macrogol 8000; macrogol 7000000; hypromellose; butylated hydroxytoluene; iron oxide yellow; magnesium stearate - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

max(rudong) chemicals co., ltd. - carfentrazone-ethyl - water dispersible granule - carfentrazone-ethyl ungrouped active 400.0 g/kg - herbicide

European Union - English - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - aerivio spiromax is indicated for use in adults aged 18 years and older only.asthmaaerivio spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:patients not adequately controlled on a lower strength corticosteroid combination product orpatients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.chronic obstructive pulmonary disease (copd)aerivio spiromax is indicated for the symptomatic treatment of patients with copd, with a fev1

European Union - English - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - airexar spiromax is indicated for use in adults aged 18 years and older only.asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.chronic obstructive pulmonary disease (copd)airexar spiromax is indicated for the symptomatic treatment of patients with copd, with a fev1

United States - English - NLM (National Library of Medicine)

the medicines company - bivalirudin (unii: tn9bex005g) (bivalirudin - unii:tn9bex005g) - bivalirudin 250 mg - angiomax is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (pci) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. angiomax is contraindicated in patients with: risk summary there are no data available on use of angiomax in pregnant women to inform a drug-associated risk of adverse developmental outcomes. reproduction studies in rats and rabbits administered subcutaneously doses up to 1.6 times and 3.2 times the maximum recommended human dose (mrhd) of 15 mg/kg/day based on body surface area (bsa) during organogenesis, respectively, revealed no evidence of fetal harm. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recogniz

United States - English - NLM (National Library of Medicine)

sandoz inc - bivalirudin (unii: tn9bex005g) (bivalirudin - unii:tn9bex005g) - angiomax is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (pci) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. angiomax is contraindicated in patients with: risk summary there are no data available on use of angiomax in pregnant women to inform a drug-associated risk of adverse developmental outcomes. reproduction studies in rats and rabbits administered subcutaneously doses up to 1.6 times and 3.2 times the maximum recommended human dose (mrhd) of 15 mg/kg/day based on body surface area (bsa) during organogenesis, respectively, revealed no evidence of fetal harm. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recogniz

United States - English - NLM (National Library of Medicine)

maia pharmaceuticals, inc. - bivalirudin (unii: tn9bex005g) (bivalirudin - unii:tn9bex005g) - angiomax rtu is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (pci), including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. angiomax rtu is contraindicated in patients with: - significant active bleeding; - hypersensitivity to angiomax rtu or its components [see adverse reactions (6.2)] . risk summary there are no available data on use of bivalirudin in pregnant women to inform a drug-associated risk of adverse developmental outcomes. reproduction studies in rats and rabbits administered subcutaneously (sc) doses up to 1.6 times and 3.2 times the maximum recommended human dose (mrhd) based on body surface area (bsa), respectively, revealed no evidence of fetal harm. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the

European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists.copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁)